Abstract：
UNASSIGNED: Nearly two decades after leucine rich repeat kinase 2 (LRRK2) was discovered as a genetic determinant of Parkinson\'s disease (PD), LRRK2 has emerged a priority therapeutic target in PD and inhibition of its activity is hypothesized to be beneficial.
UNASSIGNED: LRRK2 targeting agents, in particular kinase inhibitors and agents reducing LRRK2 expression show promise in model systems and have progressed to phase I and phase II clinical testing for PD. Several additional targeting strategies for LRRK2 are emerging, based on promoting specific \'healthy\' LRRK2 quaternary structures, heteromeric complexes and conformations.
UNASSIGNED: It can be expected that LRRK2 targeting strategies may proceed to phase III clinical testing for PD in the next five years, allowing the field to discover the real clinical value of LRRK2 targeting strategies.
UNASSIGNED: LRRK2 targeting agents, in particular kinase inhibitors and agents reducing LRRK2 expression show promise in model systems and have progressed to phase I and phase II clinical testing for PD. Several additional targeting strategies for LRRK2 are emerging, based on promoting specific \'healthy\' LRRK2 quaternary structures, heteromeric complexes and conformations.
UNASSIGNED: It can be expected that LRRK2 targeting strategies may proceed to phase III clinical testing for PD in the next five years, allowing the field to discover the real clinical value of LRRK2 targeting strategies.
摘要：
■在富含亮氨酸的重复激酶2（LRRK2）被发现是帕金森氏病（PD）的遗传决定因素近二十年后，LRRK2已成为PD中的优先治疗靶标，并且假设抑制其活性是有益的。
■LRRK2靶向剂，特别是降低LRRK2表达的激酶抑制剂和药剂在模型系统中显示出希望,并且已经进展到PD的I期和II期临床试验。LRRK2的一些其他靶向策略正在出现，基于促进特定的“健康的”LRRK2四元结构，异聚复合物和构象。
■可以预期，LRRK2靶向策略可能会在未来五年内进行PD的III期临床试验，允许该领域发现LRRK2靶向策略的真正临床价值。
■LRRK2靶向剂，特别是降低LRRK2表达的激酶抑制剂和药剂在模型系统中显示出希望,并且已经进展到PD的I期和II期临床试验。LRRK2的一些其他靶向策略正在出现，基于促进特定的“健康的”LRRK2四元结构，异聚复合物和构象。
■可以预期，LRRK2靶向策略可能会在未来五年内进行PD的III期临床试验，允许该领域发现LRRK2靶向策略的真正临床价值。
